Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Neuronal exosomes reveal Alzheimer's disease biomarkers in Down syndrome

15 Oct 2016

Abstract excerpt

INTRODUCTION: Individuals with Down syndrome (DS) exhibit Alzheimer's disease (AD) neuropathology and dementia early in life. Blood biomarkers of AD neuropathology would be valuable, as non-AD intellectual disabilities of DS and AD dementia overlap clinically. We hypothesized that elevations of amyloid β (Aβ) peptides and phosphorylated-tau in neuronal exosomes may document preclinical AD. METHODS: , P-T181-tau,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alzheimer's disease research and treatments
Share to Dementia and Cognitive Impairment Research
Share to Down syndrome and intellectual disability research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 27755974
DOI: 10.1016/j.jalz.2016.08.012

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Neuronal exosomes reveal Alzheimer's disease biomarkers in Down syndromePMID 27755974Read ↗

Proteomic analysis of Down syndrome cerebrospinal fluid compared to late-onset and autosomal dominant Alzheimer´s diseaseSemantic proximity Read ↗

Cross-Sectional Exploration of Plasma Biomarkers of Alzheimer’s Disease in Down Syndrome: Early Data from the Longitudinal Investigation for Enhancing Down Syndrome Research (LIFE-DSR) StudySemantic proximity Read ↗

Dynamics of plasma biomarkers in Down syndrome: the relative levels of Aβ42 decrease with age, whereas NT1 tau and NfL increaseSemantic proximity Read ↗

The Alzheimer's Biomarker Consortium‐Down Syndrome: Rationale and methodologySemantic proximity Read ↗

Comparison of CSF biomarkers in Down syndrome and autosomal dominant Alzheimer's disease: a cross-sectional study.Semantic proximity Read ↗

Plasma biomarkers for amyloid, tau, and cytokines in Down syndrome and sporadic Alzheimer’s diseaseSemantic proximity Read ↗

Aging with Down Syndrome—Where Are We Now and Where Are We Going?Semantic proximity Read ↗

Aging in Down Syndrome and the Development of Alzheimer's Disease NeuropathologySemantic proximity Read ↗

Longitudinal investigation for enhancing Down Syndrome Research (LIFE‐DSR) Study: Tau PET and CSF sub‐studiesSemantic proximity Read ↗

An inflammatory and trophic disconnect biomarker profile revealed in Down syndrome plasma: Relation to cognitive decline and longitudinal evaluationSemantic proximity Read ↗

From understanding to action: Exploring molecular connections of Down syndrome to Alzheimer's disease for targeted therapeutic approachSemantic proximity Read ↗

Increased levels of plasma total tau in adult Down syndromeSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.